Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzheng Huayu Tablets for First Decompensation of Hepatitis B-Related Liver Cirrhosis
NCT07017426Not yet recruiting
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- HM (Herbal Medicine)
01
Overview
Randomised, double-blind trial of fuzheng huayu in hepatitis B-related liver cirrhosis. Primary endpoint: Cumulative incidence of recurrent decompensation events at 1 year. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
fuzheng huayu
03
Conditions
hepatitis B-related liver cirrhosis
Beyond the preview
Go deeper on NCT07017426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07017426.